MABF954
Anti-LAG3 Antibody, clone 4-10-C9
clone 4-10-C9, from mouse
Synonyme(s) :
Lymphocyte activation gene 3 protein, CD223, LAG-3
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
4-10-C9, monoclonal
Espèces réactives
mouse
Technique(s)
flow cytometry: suitable
immunocytochemistry: suitable
Isotype
IgG2aκ
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
mouse ... Lag3(16768)
Description générale
Lymphocyte activation gene 3 protein (UniProt Q61790; also known as CD223, LAG-3) is encoded by the Lag3 gene (Gene ID 16768) in murine species. LAG-3 is an inhibitory T-cell surface molecule that modulates T-cell activation and homeostasis. LAG-3 co-localizes with CD8 and CD4 upon TCR engagement and alters TCR signaling. LAG-3 suppresses homeostasis proliferation (HP) of both lymphocytes and some dendritic cell populations in vivo, and enhanced HP is observed in mice deficient in LAG-3. LAG-3 signaling is shown to negatively regulate STAT5 phosphorylation in activated T cells, and no enhancement of HP was seen upon LAG-3 blockade in mice deficient in both STAT5a and STAT5b. Murine LAG-3 is produced with a signal peptide sequence (a.a. 1-22), the removal of which yields the mature protein with a large extracellular region (a.a. 23-442), followed by a transmembrane segment (a.a. 443-463) and a cytoplasmic tail (a.a. 464-521). The extracellular portion contains a V-type Ig-like domain (a.a. 37-163), followed by three C2-type Ig-like domains (a.a. 165-246, 258-341, and 345-412) and elven tandem repeats of 2-amino acid E-X seqeunce at its C-terminal end (a.a. 493-518).
Spécificité
Clone 4-10-C9 immunostained surface LAG-3 on activated CD4+ T cells by targeting an extracellular epitope within the third and fourth Ig-like domains (D3/D4 domains; second and third C2-type Ig-like domains). Surface LAG-3 degradation by pronase treatment abolished cell surface staining (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Immunogène
Epitope: Within D3/D4 domains.
Murine LAG-3-expressing mouse T-cell hybridoma.
Application
Flow Cytometry Analysis: 2.5 µg/mL from a representative lot detected surface LAG-3 immunoreactivity among the CD4+ and CD8+ populations of wild-type, but not Lag3-knockout, mouse splenocytes activated in vitro via CD3 cross-linking (Courtesy of Dario A. Vignali, Ph.D., University of Pittsburgh, PA, U.S.A.).
Flow Cytometry Analysis: A representative lot was fluorescently conjugated and detected an increased number of LAG-3-positive cells within the CD4+ and CD8+ populations of infiltrating lymphocytes (TILs) in tumors developed in mice exografted with murine B16 melanoma, MC38 colon adenocarcinoma, or Sa1N fibrosarcoma cells (Woo, S.R., et al. (2012). Cancer Res. 72(4): 917–927).
Flow Cytometry Analysis: A representative lot, pre-conjugated with Alexa Fluor™ 647, detected both surface and intracellular LAG-3 by immunofluorescent staining of non-permeabilized and permeabilized primary murine CD4+ T cells activated in vitro via CD3 & CD28 cross-linking by immobilized antibodies. Pronase treatment of cells prior to permeabilization abolished cell surface staining (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Flow Cytometry Analysis: A representative lot, pre-conjugated with Alexa Fluor 647, detected a time-dependent recovery of cell surface LAG-3 immunoreactivity on activated murine CD4+ T cells after initial surface LAG-3 degradation by pronase treatment. Protein synthesis inhibitor cycloheximide (Cat. No. 239764) or protein transport inhibitor Brefeldin A (Cat. No. 203729) treatment partially blocked the recovery (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Immunocytochemistry Analysis: A representative lot detected both surface and intracellular LAG-3 by fluorescent immunocytochemistry staining of non-permeabilized and permeabilized primary murine CD4+ T cells activated in vitro via CD3 & CD28 cross-linking by immobilized antibodies. Pronase treatment of cells prior to permeabilization abolished cell surface staining (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Immunocytochemistry Analysis: A representative lot detected intracellular LAG-3 immunoreactivity co-localized with those of the early and recycling endosome marker EEA1, as well as endosomal markers Rab11b and Rab27a by fluorescent immunocytochemistry staining of activated murine CD4+ T cells following pronase treatment and permeabilization (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Flow Cytometry Analysis: A representative lot was fluorescently conjugated and detected an increased number of LAG-3-positive cells within the CD4+ and CD8+ populations of infiltrating lymphocytes (TILs) in tumors developed in mice exografted with murine B16 melanoma, MC38 colon adenocarcinoma, or Sa1N fibrosarcoma cells (Woo, S.R., et al. (2012). Cancer Res. 72(4): 917–927).
Flow Cytometry Analysis: A representative lot, pre-conjugated with Alexa Fluor™ 647, detected both surface and intracellular LAG-3 by immunofluorescent staining of non-permeabilized and permeabilized primary murine CD4+ T cells activated in vitro via CD3 & CD28 cross-linking by immobilized antibodies. Pronase treatment of cells prior to permeabilization abolished cell surface staining (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Flow Cytometry Analysis: A representative lot, pre-conjugated with Alexa Fluor 647, detected a time-dependent recovery of cell surface LAG-3 immunoreactivity on activated murine CD4+ T cells after initial surface LAG-3 degradation by pronase treatment. Protein synthesis inhibitor cycloheximide (Cat. No. 239764) or protein transport inhibitor Brefeldin A (Cat. No. 203729) treatment partially blocked the recovery (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Immunocytochemistry Analysis: A representative lot detected both surface and intracellular LAG-3 by fluorescent immunocytochemistry staining of non-permeabilized and permeabilized primary murine CD4+ T cells activated in vitro via CD3 & CD28 cross-linking by immobilized antibodies. Pronase treatment of cells prior to permeabilization abolished cell surface staining (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
Immunocytochemistry Analysis: A representative lot detected intracellular LAG-3 immunoreactivity co-localized with those of the early and recycling endosome marker EEA1, as well as endosomal markers Rab11b and Rab27a by fluorescent immunocytochemistry staining of activated murine CD4+ T cells following pronase treatment and permeabilization (Woo, S.R., et al. (2010). Eur. J. Immunol. 40(6):1768-1777).
This Anti-LAG3 Antibody, clone 4-10-C9 is validated for use in Flow Cytometry, Immunocytochemistry for the detection of LAG3.
Qualité
Evaluated by Flow Cytometry in mouse splenocytes.
Flow Cytometry Analysis: 1 µg/mL of this antibody detected an induction of LAG-3-positive population in isolated mouse splenocytes following a 3-day 2 µg/mL Concanavalin A (Con A) stimulation.
Flow Cytometry Analysis: 1 µg/mL of this antibody detected an induction of LAG-3-positive population in isolated mouse splenocytes following a 3-day 2 µg/mL Concanavalin A (Con A) stimulation.
Description de la cible
54.51/56.98 kDa (mature/pro-form) calculated.
Forme physique
Format: Purified
Informations légales
ALEXA FLUOR is a trademark of Life Technologies
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
12 - Non Combustible Liquids
Classe de danger pour l'eau (WGK)
WGK 1
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Timo Eninger et al.
Proceedings of the National Academy of Sciences of the United States of America, 119(24), e2119804119-e2119804119 (2022-06-07)
Single-cell transcriptomics has revealed specific glial activation states associated with the pathogenesis of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. While these findings may eventually lead to new therapeutic opportunities, little is known about how these glial responses are
Yuta Morisaki et al.
Frontiers in cellular neuroscience, 17, 1308972-1308972 (2023-11-29)
Microglia are resident innate immune cells in the central nervous system (CNS) and play important roles in the development of CNS homeostasis. Excessive activation and neurotoxicity of microglia are observed in several CNS disorders, but the mechanisms regulating their activation
Marc Emmenegger et al.
EMBO molecular medicine, 13(9), e14745-e14745 (2021-07-27)
While the initial pathology of Parkinson's disease and other α-synucleinopathies is often confined to circumscribed brain regions, it can spread and progressively affect adjacent and distant brain locales. This process may be controlled by cellular receptors of α-synuclein fibrils, one
Emily Wingrove et al.
Cell reports, 27(4), 1277-1292 (2019-04-25)
The brain is a major site of relapse for several cancers, yet deciphering the mechanisms of brain metastasis remains a challenge because of the complexity of the brain tumor microenvironment (TME). To define the molecular landscape of brain metastasis from
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique